Healthcare / BiotechnologyShenzhen
$5.46
-0.04 (-0.73%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-125697.29 · quality 44.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
N/A
•EV/EBITDA
25.4x
↑ROE
-2.8%
↓Gross Margin
49.1%
↑Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.4%
FCF CAGR
+0.6%
FCF margin
3.1%
FCF / Net income
-0.29x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $514.1M · net income $-55.4M · FCF $16.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $514.1M | $514.1M | $569.7M | $579.3M | $607.0M |
| Net Income | $-55.4M | $-55.4M | $-87.4M | $-93.1M | $-90.6M |
| EBITDA | $71.6M | $71.6M | $25.6M | $27.5M | $39.4M |
| EPS | -0.17 | -0.17 | -0.27 | -0.29 | -0.28 |
| Gross Margin | 49.1% | 49.1% | 47.7% | 47.1% | 56.6% |
| Operating Margin | -7.4% | -7.4% | -9.0% | -11.1% | -10.6% |
| Net Margin | -10.8% | -10.8% | -15.3% | -16.1% | -14.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.17 | 0.13 | 0.12 |
| Current Ratio | 1.64 | 1.64 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $16.1M | $16.1M | $-125697.29 | $-101.3M | $15.8M |
| Returns | |||||
| ROE | -2.8% | -2.8% | -4.4% | -4.5% | -4.1% |
| Valuation | |||||
| EV/EBITDA | 25.36 | 25.36 | 55.64 | 71.14 | 41.95 |
| P/B | 0.89 | 0.89 | 0.67 | 0.90 | 0.76 |
| Growth & Yield | |||||
| Revenue Growth | -9.8% | -9.8% | -1.7% | -4.6% | — |
| EPS Growth | 36.6% | 36.6% | 6.1% | -2.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+27.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.27 → -0.17
Residual
+27.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.